CordenPharma

Basel – September 15, 2026 -- CordenPharma is committing €80 million in multi-year capital expenditure to expand aseptic fill-finish capacity at its FDA- and EMA-approved Caponago site near Milan, targeting total production capacity of up to 500 million sterile injectable units annually.

New 11,000-square-meter facility adds over 50% to site footprint

A key milestone within the total investment was the €13 million acquisition of a new 11,000 m2 commercial building and an adjacent 26,000 m2 plot next to the existing advanced-phase fill-finish area. The expansion, completed July 28, 2026, increases the facility's overall footprint by more than 50%.

Basel, Switzerland – September 15, 2026 -- CordenPharma has committed a multi-year €80 million investment to expand sterile injectable manufacturing at its FDA & EMA-approved Caponago site near Milan, Italy, targeting a total production capacity of 500 million units per year.

CordenPharma finalizes €13 million land and building acquisition to expand Caponago footprint by over 50%

The company completed the purchase of an 11,000 m2 commercial building and 26,000 m2 of adjacent land on 28 July 2026, adjacent to its existing late-stage aseptic fill & finish area. The new space can accommodate at least four aseptic fill & finish lines, four visual inspection lines and four packaging lines, with room for customer-owned lines, large-scale lyophilization and auto-injector assembly.

Basel – September 15, 2026 -- CordenPharma has committed a multi-year €80 million investment to expand sterile injectable manufacturing at its Caponago, Italy site, targeting total production capacity of up to 500 million injectable units per year.